据通过Telegram发送的声明，委内瑞拉国家石油公司（PDVSA）表示，目前正与美国就两国之间的商 业关系框架下的石油销售进行谈判。 声明显示，PDVSA重申致力于建立互利互惠的联盟。 该公司表示，相关运营与雪佛龙的方案类似。 据通过Telegram发送的声明，委内瑞拉国家石油公司（PDVSA）表示，目前正与美国就两国之间的商 业关系框架下的石油销售进行谈判。 新浪合作大平台期货开户 安全快捷有保障 责任编辑：丁文武 新浪合作大平台期货开户 安全快捷有保障 责任编辑：丁文武 声明显示，PDVSA重申致力于建立互利互惠的联盟。 该公司表示，相关运营与雪佛龙的方案类似。 ...

今日晚间重要公告抢先看——锋龙股份称公司控股股东拟变更为优必选，股票复牌；九连板胜通能源称 如股价进一步上涨，可能申请停牌核查；东百集团发布股价异动公告。 宏达电子：参股公司江苏展芯IPO进展尚存不确定性 宏达电子(300726)12月24日披露股票交易异常波动公告称，近期公司间接持股13.79%的参股公司江苏展 芯半导体技术股份有限公司（简称"江苏展芯"）向深交所报送了首次公开发行股票并在创业板上市的申 请文件并获受理，该事项已于12月18日进行了披露，江苏展芯IPO申报受理前后，公司对其持股比例、 表决权未出现重大变化，公司对其投资仍按权益法进行会计核算，该事项对公司当期财务报表不会构成 重大影响，且江苏展芯提交IPO申请后续进展尚存在不确定性。 海容冷链2025年前三季度利润分配预案：拟10派3元 海容冷链(603187)12月24日发布2025年前三季度利润分配预案，公司拟向全体股东每10股派发现金红利 3元（含税）。 九连板胜通能源：如股价进一步上涨 可能申请停牌核查 胜通能源(001331)12月24日公告，公司股票自12月12日以来连续9个交易日涨停，累计涨幅达135.86%， 如未来公司股票价 ...

证券日报网讯12月18日，锋尚文化（300860）在互动平台回答投资者提问时表示，公司始终积极关注全 球顶级体育。世界杯作为规模最大、商业价值最高的足球盛事，其带来的文旅融合、品牌曝光和商业合 作机会与公司业务高度契合。公司正密切关注与世界杯相关的文化演艺、创新文旅及品牌营销等合作可 能性。 ...

证券日报网讯12月17日，赣锋锂业（002460）在互动平台回答投资者提问时表示，公司已与知名无人机 及eVTOL企业达成合作，相关电池样品已进入适航认证流程，并为头部客户定制开发的高比能电芯通 过了民航局的制造符合性审查，进入实质性的商业合作与市场拓展阶段。 ...

雅乌15俱乐部主席卡雷卡·派瓦(CARECA PAIVA)当地时间15日向中新社记者证实了上述信息。对这场 差距恰好"100年"的足球赛，派瓦认真地说，"我们在你们——尤其是莆田球队身上——看到了最重要的 品质，就是谦虚、愿意学习。" 当地时间12月15日，巴西圣保罗雅乌市，即将前往中国福建莆田的雅乌足球队在绿茵场上。中新社记者 林春茵 摄 雅乌是位于巴西东南部的内陆城市，距离巴西最大城市圣保罗有4个小时车程。这里制鞋业发达，有"巴 西女鞋之都"的美誉。同时雅乌也是巴西著名的足球人才摇篮，青训体系完整。雅乌15俱乐部曾于1959 年参加巴西全国锦标赛，是享有盛名的传统足球俱乐部。 曾执教过亚洲球队的派瓦直言，就足球而言，中国目前整体水平仍弱于巴西。"并不是说中国足球很 差。最重要的是，在中国，无论是孩子、青少年，还是走向职业道路的球员，都有踢足球的强烈意 愿。" 中新网圣保罗雅乌12月16日电 题：巴西雅乌15足球队将赴华与中国莆田市足球队以球会友 派瓦坦言，"中国是当今世界上极具实力的国家之一，我们对你们的到来感到非常高兴。"以球会 友，"对我们而言是一种荣誉，对城市、对整个地区来说也是如此"。 记者 林春 ...

Financial Data and Key Metrics Changes - The company announced a $7 billion commitment to expand R&D capabilities and domestic manufacturing [6] - The cash balance remains substantial, with ongoing dividends and buybacks, but the company is open to M&A opportunities if the right conditions arise [11][12] Business Line Data and Key Metrics Changes - Eylea HD received recent approvals for RVO and Q4 dosing, with expectations for commercial impact starting in 2026 [17] - Dupixent continues to grow robustly, treating over 1.3 million patients globally, with significant market expansion opportunities in atopic dermatitis and asthma [30][31] Market Data and Key Metrics Changes - The company is actively monitoring the impact of biosimilars on Eylea, noting that any conversions to biosimilars still position patients as candidates for Eylea HD [24] - The COPD launch has shown strong performance, with Dupixent being the best-performing respiratory launch for the company [34] Company Strategy and Development Direction - The company is committed to domestic manufacturing and enhancing internal capabilities while exploring external opportunities for growth [6][12] - The focus remains on investing in the pipeline and fostering innovation to drive long-term shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, particularly regarding the Eylea HD enhancements and the ongoing growth of Dupixent [21][30] - The company is closely watching policy changes related to drug pricing and their potential impact on Eylea and other products [26] Other Important Information - The company is preparing for a submission for a prefilled syringe for Eylea HD, expected in the second quarter [18] - Linvoseltamab has shown promising data in the myeloma market, with plans for further studies in earlier lines of therapy [63] Q&A Session Summary Question: Update on policy and macro environment - The company has committed to domestic manufacturing and is in active negotiations regarding drug pricing policies [6][9] Question: Thoughts on M&A and business development - The company is open to M&A opportunities but prioritizes internal investments and collaborations [12][13] Question: Eylea HD commercial impact and competition - Eylea HD enhancements are expected to drive growth starting in 2026, despite current payer issues [21][24] Question: Dupixent growth drivers - Dupixent is benefiting from market expansion in atopic dermatitis and asthma, with significant room for growth [30][31] Question: Linvoseltamab in myeloma - Linvoseltamab has shown best-in-class data among BCMA bispecifics, with ongoing studies to simplify treatment algorithms [62][63]

Core Insights - Successful business partnerships are among the most positive and significant relationships in life, but caution and careful consideration at the outset are crucial to avoid future issues [1][12] - Many people rush into business partnerships without adequately assessing potential problems, which can lead to conflicts and pain later on [3][12] Group 1: Key Questions for Business Partnerships - Are our goals aligned? Financial motivations can vary significantly between partners, leading to tension if not discussed early [4] - How much effort will we put in? Differences in work hours and commitment levels should be clearly defined to avoid misunderstandings [5] - How do we measure contribution value? Partners must recognize that all contributions are essential and should be acknowledged [6] Group 2: Decision-Making and Conflict Resolution - How do we make tough decisions? Partners should establish a clear process for handling significant decisions when disagreements arise [7] - How do we handle conflicts? Understanding each partner's conflict resolution style is vital to maintain a healthy partnership [8] Group 3: Strategic Planning and Inequality - What is our plan? Partners need to agree on a core business strategy and how to adapt if circumstances change [10] - Where does inequality manifest? Recognizing inherent inequalities in contributions and relationships is essential for maintaining trust [10] Group 4: Profit Distribution and Documentation - How is profit distributed? Establishing clear principles for profit sharing is crucial, as it can be a sensitive topic [11] - How do we document agreements? Recording agreements is important to avoid misunderstandings and ensure all partners are on the same page [11] Group 5: Ending the Partnership - How will the partnership end? Considering the end of the partnership early can help facilitate a smoother transition when the time comes [12]

Financial Data and Key Metrics Changes - Theravance Biopharma achieved non-GAAP break-even in Q3 2025, reflecting strong execution and financial discipline [3][19] - The company ended the quarter with approximately $333 million in cash and no debt, indicating a robust financial position [4][19] - Collaboration revenue increased to $20 million, up 19% year-over-year, driven by UPELRI's strong operating leverage [19] Business Line Data and Key Metrics Changes - UPELRI net sales increased 15% year-over-year to $71.4 million, supported by strong demand growth and favorable net pricing [6][19] - UPELRI's profit margins reached record levels, with hospital volume increasing 29% year-over-year [8][10] - The company is on track to achieve a $25 million milestone from Viatris based on UPELRI's year-to-date sales performance [3][4] Market Data and Key Metrics Changes - UPELRI's share in the long-acting nebulized hospital market reached approximately 21%, a new launch-to-date high [8] - The strong growth trends for Trelegy are expected to lead to a $100 million milestone in 2026, with GSK reporting $1 billion in sales for the quarter [4][18] Company Strategy and Development Direction - The company is focused on advancing the pivotal phase III Cypress trial of ampraloxetine, with top-line results expected in early 2026 [3][16] - Theravance is committed to raising awareness of neurogenic orthostatic hypotension (NOH) associated with multiple system atrophy (MSA) through a new disease education campaign [5] - The management emphasizes the importance of executing the Cypress study and preparing for the potential launch of ampraloxetine [24][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Cypress data readout, viewing it as a significant milestone for the company [16][21] - The company remains optimistic about the transformational potential of ampraloxetine for patients with MSA-related NOH [4][21] - The management highlighted the importance of financial strength and operational execution in maximizing shareholder value [24][26] Other Important Information - The company plans to host a KOL event for investors on December 8 to discuss the unmet medical need for patients with MSA and the potential of ampraloxetine [4][17] - The company reiterated its expense guidance for 2025, expecting results to remain broadly consistent in Q4 [20] Q&A Session Summary Question: How is the company thinking about returning capital to shareholders while preparing for the launch of ampraloxetine? - Management emphasized the importance of financial strength and the need to evaluate capital return timing based on the execution of the Cypress study [24] Question: Are there any pipeline assets being considered for future opportunities? - Management stated that the focus remains on the success of ampraloxetine and UPELRI, with potential evaluations of other options post-launch [26] Question: How does the recently published manuscript inform expectations for the Cypress data? - The publication is important as it establishes a clinically meaningful difference that the company aims to replicate in the Cypress study [32][34] Question: Can the company share enrollment numbers for the randomized withdrawal portion of the Cypress study? - Management expressed confidence in the operational execution and stated that they believe the study is adequately powered [39][40]

Core Points - The Australian Trade Minister Farrell announced the participation of a record number of 256 Australian companies at the 8th China International Import Expo in Shanghai from November 5 to 10 [1] - The expo serves as a significant platform for Australian businesses to showcase high-quality goods and services to China, which is Australia's largest export market [1] - The event is expected to yield tangible results for Australian exporters, with opportunities for signing commercial cooperation memorandums worth millions of Australian dollars [1] Group 1 - The 8th China International Import Expo will take place from November 5 to 10 in Shanghai [1] - A total of 256 Australian companies will participate, marking a historical high for the event [1] - The showcased products will include dairy, meat, seafood, wine, and health products to meet the demands of the Chinese market [1] Group 2 - The expo is anticipated to create job opportunities and drive economic growth for Australia [1] - The event also provides an opportunity for Australia to promote tourism, aiming to offer world-class experiences for Chinese tourists [1] - China is expected to remain Australia's largest trading partner in the foreseeable future [1]

Core Points - A record number of 256 Australian companies are participating in the 8th China International Import Expo (CIIE), which will be held from November 5 to 10 in Shanghai [1] - Australian Trade Minister Farrell will lead this unprecedented delegation, showcasing products in high demand in the Chinese market, including packaged foods, dairy products, meat, seafood, wine, beverages, and healthcare products [1] - The CIIE provides a significant platform for Australian businesses to present their goods and services to their largest export market, contributing to job creation and economic growth [1] - The event is expected to yield tangible results for Australian exporters, with opportunities for signing commercial cooperation memorandums worth millions of Australian dollars [1] - In 2024, the bilateral trade volume between Australia and China is projected to reach 312 billion AUD, with China remaining Australia's largest trading partner [1] - The CIIE also serves as an opportunity for Australia to promote tourism, aiming to provide world-class experiences for Chinese tourists [1] Industry Insights - This year marks the eighth consecutive year that the Australian Trade and Investment Commission has established an Australian brand pavilion at the CIIE, showcasing the appeal and quality of Australian brands and products [2]